Polymeric Heart Valve

Technology #ua14-011

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Thomas Claiborne
Research Assistant Professor
Danny Bluestein
Professor, Biomedical Engineering
Marvin Slepian
Professor, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Background:  Currently, in artificial heart valves, chemically fixed animal tissue is used. While such tissue has numerous advantages in durability, it carries with it the costs of processing and implanting xenographs. Additionally, one problem with these grafts is that their durability highly depends on the age and condition of the patient. Thus, there exists a need for a highly durable, non-animal valve material which can be optimized for bloodflow and will not need anti-rejection drugs to accompany its implantation. No polymer heart valve prosthesis has made it to commercialization to date, primarily due to inferior durability compared to chemically fixed animal tissue.  

Invention: This invention discloses a novel trileaflet polymeric prosthetic heart valve that can be used in open-heart or transcatheter valve implantation, in pulsatile ventricular assist devices (or other pulsatile mechanical circulatory support devices) or the Total Artificial Heart (Syncardia ). The polymer utilized in this design is a new formulation that has not been previously applied to prosthetic heart valves, and has the potentia l for enhanced durability and hemocompatibility  over chemically fixed animal tissue and competitive polymers. Additionally, the valve leaflet has been designed with a customized variable thickness for the reduction of high stress concentrations and maximized  flexibility.

Application: This product could one day be used as a gold standard in replacing animal tissues for use in heart valves and prosthetic hearts.


This invention has been demonstrated to be superior to the state-of-the-art in (a) theory, (b) simulations, and © using real data. Our simulation results show orders of magnitude in improvement, as compared to traditional methods. Real results from data closely replicate the performance of our simulations.

  • proposed device is biosatable and hemocompatable;
  • eliminates the need for animal tissue sourcing, handling, processing, sterilization and packaging;
  • eliminates any ri sks to patients involved in implanting xenografts;
  • durability not dependent on the health and age of the patient.

Lead Inventor: Marvin J Slepian


Status: A PCT application has been filed and was published on 18 April 2013 as WO 2013/055977. This technology is managed under an Inter Institution Agreement with SUNY Stony Brook University and is available for licensing.

UA ID:  UA14-011